About PhyNexus
PhyNexus is a Healthcare company based in San Jose (United States) founded in 2002, and was acquired by Biotage in December 2018. Molecular biology research products and automated extractors are developed. PhyNexus offers products and services including BiotageĀ® Initiator+, BiotageĀ® Selekt, and ISOLUTEĀ® SCX-2. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is Biotage AB. Its competitors include ArcherDX, RareCyte and Sequenta; 3 of its 3 listed competitors have raised funding.
Company details
PhyNexus was founded in 2002 in San Jose, United States, within the biotechnology sector. Automated liquid handlers and nucleic acid extractors are produced for molecular biology applications. Operations include plasmid DNA purification kits, affinity columns, specialty resins, gel filtration systems, normal phase columns, and ion exchange columns. Benchtop robotic instruments, such as the Auto plasmid MEA, and semi-automated protein extractors are also manufactured to support research workflows.
- Headquarters San Jose, United States
- Stage Acquired
- SectorsHealthcare
- Emailā¢ā¢ā¢ā¢ā¢ā¢ā¢ā¢
- Website phynexus.com
- Social LinkedIn X Facebook
- Acquired by Biotage (Dec 2018)
- Legal Name Biotage Ab
Products & Services of PhyNexus
PhyNexus offers a comprehensive portfolio of products and services, including Biotage® Initiator+, Biotage® Selekt, and ISOLUTE® SCX-2.
Microwave synthesizer for efficient organic chemistry reactions
System for purification in drug discovery processes
Product for solid phase extraction in analytical workflows
Investors in PhyNexus
PhyNexus has secured backing from 1 investor. Prominent investors backing the company include Biotage.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | 2009 | biotage.com | Uppsala, Sweden |
Investor details for PhyNexus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of PhyNexus
2 dated milestones of PhyNexus across 16 years, from founding to its latest funding, stage changes and deals.
- Founded PhyNexus is founded.
- Exit Acquired by Biotage.
Competitors of PhyNexus
PhyNexus has 3 listed competitors in our database, 3 of them funded. They include ArcherDX, RareCyte and Sequenta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. |
Detailed competitors of PhyNexus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as PhyNexus (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track ā from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PhyNexus
PhyNexus was founded in 2002.
PhyNexus is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
PhyNexus was founded in 2002 in San Jose, United States, within the biotechnology sector. Automated liquid handlers and nucleic acid extractors are produced for molecular biology applications. Operations include plasmid DNA purification kits, affinity columns, specialty resins, gel filtration systems, normal phase columns, and ion exchange columns. Benchtop robotic instruments, such as the Auto plasmid MEA, and semi-automated protein extractors are also manufactured to support research workflows.
PhyNexus offers BiotageĀ® Initiator+, BiotageĀ® Selekt, and ISOLUTEĀ® SCX-2.
PhyNexus has 1 investor. Key investors include Biotage.
PhyNexus operates through Biotage Ab.
Yes. PhyNexus was acquired by Biotage in December 2018.